Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX3 in first-line unresectable locally advanced or metastatic pancreatic cancer
2023-505889-29-01Phase 2Authorised
- Sponsor
- Centre Georges-François Leclerc
- Start
- Feb 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of folinic acid, fluorouracil, irinotecan and oxaliplatin in pancreatic cancer (PC), sponsored by Centre Georges-François Leclerc. Planned start Feb 2024; status: authorised.
02
Drugs
folinic acidfluorouracilirinotecanoxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2023-505889-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505889-29-01.